Marketing Applications in Early 2013
The Next Big ERT? BioMarin Jumps on Solid GALNS Data
By Jennifer Boggs
Tuesday, November 6, 2012
Hailed as a key growth driver for BioMarin Pharmaceuticals Inc., GALNS (N-acetylgalactosamine-6 sulfatase) came through with solid Phase III data in rare lysosomal storage disorder mucopolysaccharidosis Type IVA (MPS IVA), sending shares of the Novato, Calif.-based biotech soaring 31.2 percent Monday.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.